Last reviewed · How we verify
NCT05212831: RESTORE
Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.
NA trial testing Inogen One® G4 in COVID-19 in 21 participants. Completed in 2 March 2023.
2 March 2023
Quick facts
| Lead sponsor | Inogen Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 8 June 2022 |
| Primary completion | 2 March 2023 |
| Estimated completion | 2 March 2023 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Inogen One® G4
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Inogen Inc. — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, open label, randomized, crossover, pilot, exploratory study to describe the effect of the Inogen One® G4 POC on brain hypoxia, peripheral oxygen saturation and cognitive function in adults with longterm- COVID.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interventions for mental health, cognition, and psychological wellbeing in long COVID: a systematic review of registered trials.
Hawke LD, Nguyen ATP, Ski CF, Thompson DR, et al · · 2022 · cited 45× · PMID 35768406 · DOI 10.1017/s0033291722002203
Verify or expand the search:
- PubMed search for NCT05212831
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Inogen Inc. trials
Trials by the same sponsor.
- NCT06555484 — Acute Effects of Supplemental Oxygen on Memory Testing in Healthy Adult Volunteers · NA · completed
- NCT06000332 — Evaluation of POC Pulse-dose Demand Oxygen Delivery for Nocturnal Hypoxemia · NA · completed
- NCT05719363 — Portable Oxygen Concentrator in Non-hospitalized Patients With Chronic Heart Failure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05212831 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inogen Inc.
- Last refreshed: 14 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05212831.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing